Living With Multiple Sclerosis (MS)

Dean speaks about his diagnostic


Like Dean, who lives in Queensland, Australia, about two million people worldwide are living with multiple sclerosis. For each of them, when the diagnosis comes, another life begins.

Living with Multiple Sclerosis means accepting and rising above the diagnosis, fighting every day to live the best life possible. It is also means resetting priorities, as shared by Dean:

“Before MS, I thought only of my career… today, it’s only my family that counts.”

Bringing Hope

Multiple Sclerosis (MS) is a complex, multifaceted chronic disease that affects each person differently. MS may evolve through relapses or continuously, which leads to a constant progression of the disability. To meet their commitment to patients, Sanofi and Genzyme, a Sanofi company, offer two new treatments that have been approved by the European Commission in 2013 for Relapsing forms of the disease. Once-daily oral Aubagio®(teriflunomide)1 and Lemtrada™ (alemtuzumab)1, are new therapeutic options developed according to the needs of patients, particularly regarding the drug’s way of administration. Current treatments aim to reduce the frequency of relapses, to slow down the progression of the disease, and in doing so to reduce the consequences of disability in the patients’ daily lives.

Genzyme is also advancing its pipeline with new collaborations and research into potential treatments for progressive forms of MS, as well as treatments that can protect and repair the brain

Understanding Multiple Sclerosis (MS)

Multiple sclerosis is considered to be an immune-mediated disease in which the body’s immune system attacks the central nervous system (CNS). There are four clinical forms of the disease: Relapsing-Remitting, Secondary-Progressive, Primary-Progressive and Progressive Relapsing. Approximately 85% of patients are initially diagnosed with the Relapsing-Remitting form of MS.



  1. Currently approved in more than 30 countries.
Choose the topics that interest you, like: